Your browser doesn't support javascript.
Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study.
Tanimoto, Takuya; Tada, Shinpei; Fujita, Suguru; Hirakawa, Tetsu; Matsumura, Mirai; Isoyama, Shoko; Ueno, Sayaka; Hamai, Kosuke; Tsuji, Naoki; Hirosawa, Hideyasu; Taniguchi, Tomohiro; Okamoto, Takeshi; Omoto, Takuji; Kusunoki, Shinji; Maeda, Hiroyuki; Ishikawa, Nobuhisa.
  • Tanimoto T; Department of Respiratory Medicine, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan. Electronic address: t-tanimoto@hph.pref.hiroshima.jp.
  • Tada S; Department of Respiratory Medicine, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
  • Fujita S; Department of Respiratory Internal Medicine, JA Hiroshima General Hospital, 1-3-3, Jigozen, Hatsukaichi, 738-8503, Japan.
  • Hirakawa T; Department of Respiratory Medicine, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
  • Matsumura M; Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • Isoyama S; Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
  • Ueno S; Department of Respiratory Medicine, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
  • Hamai K; Department of Respiratory Medicine, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
  • Tsuji N; Department of General Internal Medicine and Infectious Diseases, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
  • Hirosawa H; Department of General Internal Medicine and Infectious Diseases, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
  • Taniguchi T; Department of General Internal Medicine and Infectious Diseases, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
  • Okamoto T; Department of General Internal Medicine and Infectious Diseases, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
  • Omoto T; Department of Rheumatology, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
  • Kusunoki S; Department of Emergency and Critical Care Medicine, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
  • Maeda H; Department of Rheumatology, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
  • Ishikawa N; Department of Respiratory Medicine, Hiroshima Prefectural Hospital, 1-5-54, Ujinakanda, Minami-ku, Hiroshima, 734-8530, Japan.
Respir Investig ; 60(3): 418-424, 2022 May.
Article in English | MEDLINE | ID: covidwho-1751178
ABSTRACT
In this retrospective cohort study, we evaluated the efficacy of baricitinib in the treatment of coronavirus disease 2019 (COVID-19). Among 404 adult patients with COVID-19 who were admitted to our hospital between October 23, 2020, and July 31, 2021, 229 patients with respiratory failure were included. Among these, 41 patients in the baricitinib group and 41 patients in the control group were selected by propensity score matching to adjust for background factors. We compared the survival rates of the two groups at 30 and 60 days after admission. The 30-day survival rate was significantly higher in the baricitinib group than in the control group. However, there was no significant difference in 60-day survival in the two groups. Baricitinib may improve the early prognosis of patients with respiratory failure associated with COVID-19. However, efforts should be made to improve the long-term prognosis.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Insufficiency / COVID-19 / COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Adult / Humans Language: English Journal: Respir Investig Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Insufficiency / COVID-19 / COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Adult / Humans Language: English Journal: Respir Investig Year: 2022 Document Type: Article